About Charles River Laboratories International
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NYSE
- Symbol: CRL
- CUSIP: 15986410
Key Metrics:
- Previous Close: $82.76
- 50 Day Moving Average: $82.50
- 200 Day Moving Average: $81.98
- 52-Week Range: $59.99 - $89.18
- Trailing P/E Ratio: 27.96
- Foreward P/E Ratio: 16.26
- P/E Growth: 1.49
- Market Cap: $3.91B
- Outstanding Shares: 47,293,000
- Beta: 1.21
Profitability:- Net Margins: 9.49%
- Return on Equity: 25.18%
- Return on Assets: 8.92%
Debt:- Debt-to-Equity Ratio: 1.54%
- Current Ratio: 1.70%
- Quick Ratio: 1.46%
Additional Links:
Companies Related to Charles River Laboratories International:
Earnings History for Charles River Laboratories International (NYSE:CRL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2016 | | | | | | | | |
| 8/3/2016 | Q216 | $1.10 | $1.20 | $425.05 million | $434.10 million | View | Listen |  |
| 5/4/2016 | Q116 | $0.90 | $0.98 | $354.92 million | $354.90 million | View | Listen | |
| 2/10/2016 | Q415 | $0.94 | $1.00 | $349.20 million | $353.90 million | View | Listen | |
| 11/4/2015 | Q315 | $0.94 | $1.03 | $340.09 million | $349.50 million | View | Listen | |
| 7/30/2015 | Q215 | $0.97 | $0.96 | $338.30 million | $339.60 million | View | Listen | |
| 4/29/2015 | Q115 | $0.82 | $0.79 | $324.00 million | $320.40 million | View | Listen | |
| 2/10/2015 | Q414 | $0.72 | $0.81 | $318.73 million | $329.50 million | View | Listen | |
| 10/29/2014 | Q314 | $0.80 | $0.86 | $326.70 million | $327.60 million | View | Listen | |
| 8/6/2014 | Q214 | $0.82 | $0.97 | $327.96 million | $341.18 million | View | Listen | |
| 4/30/2014 | Q114 | $0.74 | $0.82 | $302.08 million | $299.40 million | View | Listen | |
| 2/12/2014 | Q413 | $0.68 | $0.73 | $289.56 million | $289.20 million | View | Listen | |
| 10/30/2013 | Q313 | $0.70 | $0.79 | $290.28 million | $292.10 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.71 | $0.73 | $293.77 million | $294.40 million | View | Listen | |
| 5/1/2013 | Q1 2013 | $0.71 | $0.69 | $294.53 million | $291.20 million | View | Listen | |
| 2/13/2013 | Q4 2012 | $0.60 | $0.64 | $280.81 million | $280.10 million | View | Listen | |
| 10/30/2012 | | $0.62 | $0.65 | | | View | N/A | |
| 8/7/2012 | | $0.66 | $0.75 | | | View | N/A | |
| 5/2/2012 | | $0.65 | $0.70 | | | View | N/A | |
| 2/13/2012 | | $0.56 | $0.69 | | | View | N/A | |
| 11/1/2011 | | $0.58 | $0.57 | | | View | N/A | |
| 8/2/2011 | | $0.60 | $0.70 | | | View | N/A | |
| 5/3/2011 | | $0.55 | $0.61 | | | View | N/A | |
| 2/8/2011 | | $0.50 | $0.60 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Charles River Laboratories International (NYSE:CRL)Current Year EPS Consensus Estimate: $4.46 EPS
Next Year EPS Consensus Estimate: $5.09 EPS
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2016 | 9 | $0.84 | $0.95 | $0.91 |
| Q2 2016 | 6 | $1.09 | $1.13 | $1.11 |
| Q3 2016 | 5 | $1.12 | $1.14 | $1.14 |
| Q4 2016 | 5 | $1.13 | $1.16 | $1.15 |
| Q1 2017 | 3 | $1.07 | $1.19 | $1.14 |
| Q2 2017 | 3 | $1.25 | $1.33 | $1.28 |
| Q3 2017 | 2 | $1.28 | $1.32 | $1.30 |
| Q4 2017 | 2 | $1.30 | $1.40 | $1.35 |
(Data provided by Zacks Investment Research)
Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Charles River Laboratories International (NYSE:CRL)Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 96.19%
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/30/2016 | Davide Molho | Insider | Sell | 7,877 | $84.10 | $662,455.70 | |
| 8/5/2016 | James C Foster | Chairman | Sell | 18,351 | $85.63 | $1,571,396.13 | |
| 7/29/2016 | Richard F Wallman | Director | Sell | 7,740 | $88.00 | $681,120.00 | |
| 7/1/2016 | George Massaro | Director | Sell | 3,740 | $83.09 | $310,756.60 | |
| 5/24/2016 | John J Crowley | CAO | Sell | 1,913 | $85.00 | $162,605.00 | |
| 5/13/2016 | Richard F Wallman | Director | Sell | 1,970 | $82.32 | $162,170.40 | |
| 5/10/2016 | Richard F Wallman | Director | Sell | 11,990 | $84.00 | $1,007,160.00 | |
| 5/9/2016 | George Massaro | Director | Sell | 985 | $82.17 | $80,937.45 | |
| 5/6/2016 | Richard F Wallman | Director | Sell | 2,720 | $81.00 | $220,320.00 | |
| 4/6/2016 | Davide Molho | VP | Sell | 30,667 | $80.00 | $2,453,360.00 | |
| 3/2/2016 | Nancy Gillett | VP | Sell | 7,015 | $75.00 | $526,125.00 | |
| 2/29/2016 | Nancy Gillett | VP | Sell | 3,646 | $73.50 | $267,981.00 | |
| 2/25/2016 | David P Johst | VP | Sell | 34,075 | $73.02 | $2,488,156.50 | |
| 2/24/2016 | James C Foster | CEO | Sell | 3,873 | $70.40 | $272,659.20 | |
| 2/23/2016 | George M Milne Jr | Director | Sell | 10,440 | $73.02 | $762,328.80 | |
| 2/22/2016 | James C Foster | CEO | Sell | 9,831 | $73.12 | $718,842.72 | |
| 2/12/2016 | C Richard Reese | Director | Sell | 4,228 | $71.48 | $302,217.44 | |
| 2/12/2016 | Nancy Gillett | VP | Sell | 6,750 | $71.90 | $485,325.00 | |
| 2/1/2016 | Stephen D Chubb | Director | Sell | 2,000 | $74.76 | $149,520.00 | |
| 12/17/2015 | George Massaro | Director | Sell | 7,740 | $80.00 | $619,200.00 | |
| 12/17/2015 | Thomas F. Ackerman | insider | Sell | 10,000 | $80.00 | $800,000.00 | |
| 11/19/2015 | Thomas F. Ackerman | insider | Sell | 10,000 | $75.00 | $750,000.00 | |
| 11/4/2015 | Thomas F. Ackerman | insider | Sell | 21,612 | $70.01 | $1,513,056.12 | |
| 11/2/2015 | Stephen D Chubb | Director | Sell | 2,000 | $66.57 | $133,140.00 | |
| 8/17/2015 | Thomas F Ackerman | Insider | Sell | 5,000 | $75.53 | $377,650.00 | |
| 5/15/2015 | Thomas F Ackerman | CFO | Sell | 3,900 | $70.51 | $274,989.00 | |
| 5/7/2015 | George Massaro | Director | Sell | 1,360 | $70.21 | $95,485.60 | |
| 3/3/2015 | Stephen D Chubb | Director | Sell | 2,000 | $75.52 | $151,040.00 | |
| 3/2/2015 | Deborah Turner Kochevar | Director | Sell | 2,600 | $76.59 | $199,134.00 | |
| 3/2/2015 | James C Foster | CEO | Sell | 2,036 | $76.93 | $156,629.48 | |
| 3/2/2015 | Nancy Gillett | VP | Sell | 4,379 | $76.72 | $335,956.88 | |
| 2/27/2015 | Nancy Gillett | VP | Sell | 2,772 | $76.95 | $213,305.40 | |
| 2/25/2015 | James C Foster | CEO | Sell | 4,621 | $75.96 | $351,011.16 | |
| 2/25/2015 | Nancy Gillett | VP | Sell | 5,015 | $76.12 | $381,741.80 | |
| 2/24/2015 | James C Foster | CEO | Sell | 4,800 | $75.70 | $363,360.00 | |
| 2/24/2015 | Jorg Geller | VP | Sell | 12,061 | $76.17 | $918,686.37 | |
| 2/23/2015 | James C Foster | CEO | Sell | 8,423 | $76.56 | $644,864.88 | |
| 2/23/2015 | Jorg Geller | VP | Sell | 7,041 | $76.59 | $539,270.19 | |
| 2/20/2015 | George M Milne Jr | Director | Sell | 6,000 | $75.87 | $455,220.00 | |
| 2/19/2015 | James C Foster | CEO | Sell | 9,671 | $75.00 | $725,325.00 | |
| 2/18/2015 | Stephen D Chubb | Director | Sell | 5,011 | $73.97 | $370,663.67 | |
| 2/17/2015 | Jorg Geller | VP | Sell | 14,430 | $73.54 | $1,061,182.20 | |
| 2/17/2015 | Thomas F Ackerman | CFO | Sell | 4,400 | $73.50 | $323,400.00 | |
| 2/13/2015 | Davide Molho | VP | Sell | 19,075 | $74.00 | $1,411,550.00 | |
| 2/12/2015 | Jorg Geller | VP | Sell | 8,458 | $73.68 | $623,185.44 | |
| 1/26/2015 | Thomas F Ackerman | CFO | Sell | 10,000 | $70.00 | $700,000.00 | |
| 1/8/2015 | David P Johst | VP | Sell | 4,737 | $67.00 | $317,379.00 | |
| 1/7/2015 | David P Johst | VP | Sell | 26,100 | $65.00 | $1,696,500.00 | |
| 12/1/2014 | Stephen D Chubb | Director | Sell | 2,000 | $64.44 | $128,880.00 | |
| 11/28/2014 | David P Johst | VP | Sell | 6,982 | $65.34 | $456,203.88 | |
| 11/17/2014 | Thomas F Ackerman | CFO | Sell | 10,000 | $63.70 | $637,000.00 | |
| 11/14/2014 | Jorg Geller | VP | Sell | 5,610 | $63.57 | $356,627.70 | |
| 11/6/2014 | C Richard Reese | Director | Sell | 5,849 | $63.39 | $370,768.11 | |
| 11/4/2014 | John J Crowley | CAO | Sell | 1,000 | $64.00 | $64,000.00 | |
| 11/3/2014 | Davide Molho | VP | Sell | 16,402 | $64.54 | $1,058,585.08 | |
| 11/3/2014 | George Massaro | Director | Sell | 16,710 | $65.00 | $1,086,150.00 | |
| 11/3/2014 | Thomas F Ackerman | CFO | Sell | 36,100 | $65.00 | $2,346,500.00 | |
| 10/30/2014 | Nancy Gillett | VP | Sell | 1,069 | $65.00 | $69,485.00 | |
| 10/28/2014 | David P Johst | VP | Sell | 74,780 | $64.00 | $4,785,920.00 | |
| 10/3/2014 | James C Foster | CEO | Sell | 136,647 | $62.00 | $8,472,114.00 | |
| 9/29/2014 | Thomas F Ackerman | CFO | Sell | 5,000 | $60.00 | $300,000.00 | |
| 9/4/2014 | Davide Molho | VP | Sell | 4,900 | $61.34 | $300,566.00 | |
| 9/2/2014 | Stephen D Chubb | Director | Sell | 2,000 | $59.18 | $118,360.00 | |
| 8/26/2014 | George Massaro | Director | Sell | 10,440 | $60.00 | $626,400.00 | |
| 8/18/2014 | Thomas F Ackerman | CFO | Sell | 23,156 | $59.25 | $1,371,993.00 | |
| 8/12/2014 | Richard F Wallman | Director | Sell | 3,240 | $58.20 | $188,568.00 | |
| 6/2/2014 | Stephen D Chubb | Director | Sell | 2,000 | $52.93 | $105,860.00 | |
| 5/22/2014 | Deborah Turner Kochevar | Director | Sell | 3,100 | $53.30 | $165,230.00 | |
| 5/8/2014 | George Massaro | Director | Sell | 1,620 | $52.70 | $85,374.00 | |
| 5/5/2014 | Thomas Ackerman | CFO | Sell | 5,430 | $50.76 | $275,626.80 | |
| 3/7/2014 | Nancy Gillett | VP | Sell | 10,110 | $58.36 | $590,019.60 | |
| 3/4/2014 | Nancy Gillett | VP | Sell | 13,650 | $58.98 | $805,077.00 | |
| 3/3/2014 | Stephen Chubb | Director | Sell | 2,000 | $58.70 | $117,400.00 | |
| 2/28/2014 | Jorg Geller | VP | Sell | 7,486 | $59.41 | $444,743.26 | |
| 2/27/2014 | Nancy Gillett | VP | Sell | 4,000 | $60.00 | $240,000.00 | |
| 2/25/2014 | Jorg Geller | VP | Sell | 3,188 | $58.49 | $186,466.12 | |
| 2/20/2014 | Nancy Gillett | VP | Sell | 4,000 | $58.96 | $235,840.00 | |
| 2/19/2014 | Stephen Chubb | Director | Sell | 5,198 | $58.35 | $303,303.30 | |
| 2/18/2014 | Thomas Ackerman | CFO | Sell | 14,000 | $58.05 | $812,700.00 | |
| 1/13/2014 | David Johst | VP | Sell | 19,750 | $58.00 | $1,145,500.00 | |
| 1/7/2014 | George Massaro | Director | Sell | 5,750 | $54.00 | $310,500.00 | |
| 12/20/2013 | Thomas Ackerman | CFO | Sell | 5,000 | $52.72 | $263,600.00 | |
| 12/4/2013 | Jorg Geller | VP | Sell | 7,200 | $51.93 | $373,896.00 | |
| 12/2/2013 | Stephen Chubb | Director | Sell | 2,000 | $51.92 | $103,840.00 | |
| 9/16/2013 | George Massaro | Director | Sell | 5,958 | $47.38 | $282,290.04 | |
| 9/9/2013 | James C Foster | CEO | Sell | 174,479 | $47.00 | $8,200,513.00 | |
| 9/4/2013 | Thomas F Ackerman | CFO | Sell | 6,100 | $46.13 | $281,393.00 | |
| 9/3/2013 | Stephen Chubb | Director | Sell | 2,000 | $46.49 | $92,980.00 | |
| 8/29/2013 | James Foster | CEO | Sell | 40,983 | $47.00 | $1,926,201.00 | |
| 8/22/2013 | Davide Molho | VP | Sell | 6,500 | $47.93 | $311,545.00 | |
| 8/20/2013 | Stephen Chubb | Director | Sell | 4,000 | $47.46 | $189,840.00 | |
| 8/5/2013 | Jorg Geller | VP | Sell | 3,025 | $46.38 | $140,299.50 | |
| 8/5/2013 | Richard Wallman | Director | Sell | 1,500 | $45.95 | $68,925.00 | |
| 8/2/2013 | Davide Molho | VP | Sell | 4,100 | $45.89 | $188,149.00 | |
| 8/2/2013 | Deborah Turner Kochevar | Director | Sell | 4,447 | $46.02 | $204,650.94 | |
| 8/2/2013 | Thomas Ackerman | CFO | Sell | 26,250 | $46.03 | $1,208,287.50 | |
| 6/3/2013 | Thomas F Ackerman | CFO | Sell | 4,000 | $42.40 | $169,600.00 | |
| 5/14/2013 | James C Foster | CEO | Sell | 113,810 | $45.00 | $5,121,450.00 | |
| 5/10/2013 | George Massaro | Director | Sell | 2,020 | $44.09 | $89,061.80 | |
| 3/13/2013 | David P Johst | VP | Sell | 17,038 | $45.00 | $766,710.00 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Charles River Laboratories International (NYSE:CRL)| Date | Headline |
|---|
 | Charles River And The Tri-Institutional Therapeutics Discovery Institute Announce Strategic Partnership (NYSE:CRL)
www.biospace.com - September 24 at 9:07 AM |
 | Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic Partnership - Business Wire (press release) (NYSE:CRL)
www.businesswire.com - September 23 at 9:32 AM |
 | Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic Partnership - Yahoo Finance (NYSE:CRL)
finance.yahoo.com - September 22 at 4:33 PM |
 | Charles River Laboratories Intl : and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic Partnership (NYSE:CRL)
www.4-traders.com - September 22 at 10:00 AM |
 | Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce Strategic Partnership (NYSE:CRL)
www.publicnow.com - September 22 at 10:00 AM |
| Stock Update: Estimates & Target in Focus for Charles River Laboratories International, Inc. (NYSE:CRL) - Frisco Fastball (NYSE:CRL)
friscofastball.com - September 21 at 4:59 PM |
| Shares Have Ticked Up Over the Last Five Trading Sessions: Charles River Laboratories International, Inc. (NYSE:CRL) - Post News (NYSE:CRL)
www.kentuckypostnews.com - September 20 at 10:13 AM |
 | Jim Cramer's Top Takeaways: Impinj, Charles River Labs (NYSE:CRL)
www.thestreet.com - September 13 at 9:13 AM |
| Charles River Laboratories International, Inc. (NYSE:CRL): How Are Analysts Advising to Play This Stock? - Post News (NYSE:CRL)
www.kentuckypostnews.com - September 12 at 4:12 PM |
| Stock on the Rise Over the Last Half Year: Charles River Laboratories International, Inc. (NYSE:CRL) - Post News (NYSE:CRL)
www.kentuckypostnews.com - September 12 at 4:12 PM |
 | CRL Crosses Below Key Moving Average Level (NYSE:CRL)
www.nasdaq.com - September 10 at 4:09 PM |
| Charles River Laboratories International, Inc. (NYSE:CRL): What is the Sell-side Making of this Stock? - National Daily Press (NYSE:CRL)
www.nationaldailypress.com - September 10 at 9:01 AM |
| Institutional Investors Have Decreased Positions in Charles River Laboratories International, Inc. (NYSE:CRL) - Post News (NYSE:CRL)
www.kentuckypostnews.com - September 9 at 4:18 PM |
| Placing Charles River Laboratories International, Inc. (NYSE:CRL) Shares Under the Microscope - Post News (NYSE:CRL)
www.kentuckypostnews.com - September 9 at 4:18 PM |
| Charles River Laboratories International, Inc. (NYSE:CRL) From The Analysts Point of View - National Daily Press (NYSE:CRL)
www.nationaldailypress.com - September 9 at 4:18 PM |
| Stock Sliding Down Over the Last Month: Charles River Laboratories International, Inc. (NYSE:CRL) - Post News (NYSE:CRL)
www.kentuckypostnews.com - September 8 at 8:10 AM |
| Charles River Laboratories to Present at September Investor Conferences - Yahoo Sports (NYSE:CRL)
sports.yahoo.com - September 6 at 9:21 PM |
| Charles River downgraded by UBS (NYSE:CRL)
finance.yahoo.com - September 6 at 9:21 PM |
| Charles River Laboratories to Present at September Investor Conferences (NYSE:CRL)
finance.yahoo.com - September 6 at 9:18 AM |
 | Can Shares Of Charles River Laboratories International, Inc. (NYSE:CRL) Get To $100? - Investor Newswire (NYSE:CRL)
www.investornewswire.com - September 3 at 9:02 AM |
 | Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish Manner : CRL-US : August 31, 2016 (NYSE:CRL)
www.capitalcube.com - August 31 at 9:13 AM |
| It's Earnings Time: What to Do with Charles River Laboratories International, Inc. (NYSE:CRL) Stock - The Voice Registrar (NYSE:CRL)
voiceregistrar.com - August 27 at 4:12 PM |
 | Charles River Laboratories International, Inc. (NYSE:CRL) Paying ... - Stocks Daily (NYSE:CRL)
www.stocksdaily.net - August 25 at 4:29 PM |
 | Moody's Upgrades Two, Affirms Three and Downgrades One Class of MLCFC 2006-2 (NYSE:CRL)
www.moodys.com - August 18 at 9:39 PM |
| Will Charles River Laboratories International, Inc. (NYSE:CRL) Hit $100 Price Target? - Investor Newswire (NYSE:CRL)
www.investornewswire.com - August 17 at 9:48 PM |
| Charles River Laboratories announces partnership with the Milner Therapeutics Institute and Consortium - Drug Target Review (NYSE:CRL)
www.drugtargetreview.com - August 11 at 10:14 PM |
| Will This Clinical Researcher Become Next Breakout Medical Stock? (NYSE:CRL)
finance.yahoo.com - August 11 at 4:32 PM |
| CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials (NYSE:CRL)
finance.yahoo.com - August 10 at 4:29 PM |
| ETF’s with exposure to Charles River Laboratories International, Inc. : August 10, 2016 (NYSE:CRL)
www.capitalcube.com - August 10 at 4:29 PM |
| Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : August 9, 2016 (NYSE:CRL)
www.capitalcube.com - August 9 at 10:50 AM |
| Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and Consortium - Business Wire (press release) (NYSE:CRL)
www.businesswire.com - August 8 at 9:47 PM |
| Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NYSE:CRL)
www.capitalcube.com - August 8 at 4:29 PM |
 | Charles River Laboratories International Inc (NYSE:CRL) Announced Q2 Profit of $35.2 Million - Street Report (NYSE:CRL)
www.streetreport.co - August 5 at 11:13 AM |
 | Charles River Laboratories International's (CRL) CEO Jim Foster on Q2 2016 Results - Earnings Call Transcript (NYSE:CRL)
seekingalpha.com - August 4 at 4:35 PM |
| Strong Sell Calls For Charles River Laboratories International, Inc. (NYSE:CRL) At 1 - Investor Newswire (NYSE:CRL)
www.investornewswire.com - August 4 at 10:50 AM |
| Charles River Laboratories International Inc. (NYSE:CRL) Earnings Beat Consensus Estimates - BNB Daily (blog) (NYSE:CRL)
www.baseball-news-blog.com - August 3 at 10:03 PM |
| Edited Transcript of CRL earnings conference call or presentation 3-Aug-16 12:30pm GMT (NYSE:CRL)
finance.yahoo.com - August 3 at 10:03 PM |
| Charles River Q2 Results Top Estimates; Lifts FY16 Adj. EPS, Revenue Growth View (NYSE:CRL)
www.nasdaq.com - August 3 at 10:38 AM |
 | Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations (NYSE:CRL)
www.tmcnet.com - August 3 at 10:38 AM |
 | Charles River Laboratories International Inc.: Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations (NYSE:CRL)
www.twst.com - August 3 at 10:38 AM |
 | Charles River Laboratories International Inc. Profit Climbs 25% In Q2 (NYSE:CRL)
www.rttnews.com - August 3 at 10:38 AM |
| Charles River beats Street 2Q forecasts (NYSE:CRL)
sg.finance.yahoo.com - August 3 at 10:38 AM |
| CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Finan (NYSE:CRL)
biz.yahoo.com - August 3 at 10:38 AM |
| Charles River Laboratories International Inc Earnings Call scheduled for 8:30 am ET today (NYSE:CRL)
biz.yahoo.com - August 3 at 10:38 AM |
| Can Shares Of Charles River Laboratories International, Inc. (NYSE:CRL) Hit $97? - Investor Newswire (NYSE:CRL)
www.investornewswire.com - July 27 at 10:05 PM |
| Charles River Laboratories International Reaches Analyst Target Price - Nasdaq (NYSE:CRL)
www.nasdaq.com - July 27 at 10:05 PM |
| Earnings Focus and Crowd Sourced Sentiment Review for Charles River Laboratories International, Inc. (NYSE:CRL) - TGP (NYSE:CRL)
telanaganapress.com - July 22 at 10:50 AM |
 | Fox Run Management L.l.c. adds Charles River Laboratories (CRL) to its portfolio - Trade Calls (NYSE:CRL)
www.tradecalls.org - July 22 at 10:50 AM |
| Shares Positive Over the Past Month: Charles River Laboratories International, Inc. (NYSE:CRL) - TGP (NYSE:CRL)
telanaganapress.com - July 21 at 5:58 AM |
| Are Analysts Bullish Charles River Laboratories Intl. Inc (NYSE:CRL) After Last Week? - Press Telegraph (NYSE:CRL)
presstelegraph.com - July 21 at 5:58 AM |
Charles River Laboratories International (NYSE:CRL) Chart for Saturday, September, 24, 2016
